Adverse effects after vaccination against SARS-CoV-2 (COVID-19) in Down syndrome adults

Michele Lacerda de Andrade; Laura Uehara; Janaina Ferreira de Moraes; João Carlos Ferrari Corrêa; Fernanda Ishida Corrêa

doi:10.5585/22.2023.23794

Autores

Michele Lacerda de Andrade Universidade Nove de Julho (UNINOVE) http://orcid.org/0000-0002-2763-8042
Laura Uehara Universidade Nove de Julho (UNINOVE) http://orcid.org/0000-0002-3941-859X
Janaina Ferreira de Moraes Universidade Nove de Julho (UNINOVE) http://orcid.org/0000-0002-8267-8557
João Carlos Ferrari Corrêa Universidade Nove de Julho (UNINOVE) http://orcid.org/0000-0002-8642-9814
Fernanda Ishida Corrêa Universidade Nove de Julho (UNINOVE) http://orcid.org/0000-0001-7321-6257

DOI:

https://doi.org/10.5585/22.2023.23794

Palavras-chave:

Síndrome de Down, Vacinas, COVID-19, Efeitos Adversos.

Resumo

Introdução: Comorbidades em adultos com síndrome de Down são comuns tornando-os um grupo de risco para COVID-19. Dessa forma, vacinar contra a COVID-19 torna-se necessária, mas requer cuidados contra possíveis efeitos colaterais.
Objetivo: Pesquisar possíveis efeitos adversos após vacinação contra COVID-19 em adultos com Síndrome de Down (SD).
Metodologia: Estudo descritivo no qual 97 adultos diagnosticados com SD foram entrevistados por meio de um questionário contendo dezessete questões relacionadas a dados pessoais e histórico, e sete questões relacionadas à vacinação.
Resultados: A vacina mais aplicada foi a AstraZeneca (94%), Pfizer (4%) e CoronaVac (2%); 74% dos sujeitos apresentaram efeitos adversos, sendo os mais frequentes após a primeira dose: dor no local da injeção (65,3%), febre (37,9%), dores musculares (37,8%), mal-estar (29,5%); na segunda dose houve diminuição desses efeitos adversos; 95% dos sintomas desapareceram após as primeiras 24 horas após a aplicação.
Conclusão: Mais da metade dos indivíduos entrevistados apresentou efeitos adversos após a aplicação da primeira dose da vacina, diminuindo com a segunda dose; a mais frequente foi a dor no local de aplicação.

Downloads

Não há dados estatísticos.

Referências

Huang C, Wang Y, Li. X, Ren. L, Zhao. J, Hu. Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lanceta. 2020;(January):19–21.

Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020;35(5):1545–9.

Gómes CC, Rodriguez ÓP, Torné ML, Santaolalla CE, Jiménez JFM, Fernández JG, et al. Clinical Consensus Recommendations Regarding Non-Invasive Respiratory Support in the Adult Patient with Acute Respiratory Failure Secondary to SARS-CoV-2 infection. Arch Bronconeumol. 2020;56:11–8.

Silva AC, Heidemann AM, Cunha AA, Monte ABFO , Monteiro ACDCG, Vian BS, Et Al. Manual De Condutas Assistência Fisioterapêutica No. 2020.

Ministério da Saúde. Manejo Clínico Protocolo da COVID-19 de Manejo Clínico na Atenção Especializada Protocolo da COVID-19. 2020.

Murbe D, Kriegel M, Lange J, Schumann L, Hartmann A, Fleischer M. Aerosol emission of adolescents voices during speaking, singing and shouting. PLoS One. 2021;16(2 February):1–10.

World Health Organization W. Timeline: WHO response COVID-19. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline (acessado em 02/Dez/2020). 2021;2019–21.

GOV.UK. Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine. Medicines & Healthcare products Regulatory Agency. (https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-COVID-19/conditions-of-authorisation-for-pfizerbiontech-COVID-19-vaccine). 2020; Conditions. (Regulamento 174):1–9.

GOV.UK. Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine. Medicines & Healthcare products Regulatory Agency. (https://www.gov.uk/government/publications/regulatory-approval-of-COVID-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-COVID-19-vaccine-astrazeneca). 2020;(Regulamento 174):1–15.

GOV.UK. UK medicines regulator gives approval for first UK COVID-19 vaccine. Medicines & Healthcare products Regulatory Agency. (https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-COVID-19-vaccine). 2020;2020–3.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-rammerstorfer S, et al. Articles Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1 / 2 , single-blind , randomised controlled trial. 2020;467–78.

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. New England Journal of Medicine. 2021;384(23):2187–201.

Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–93.

Butantan I. Vacina contra a COVID-19. https://vacinacovid.butantan.gov.br/vacinas. 2021;19:19–20.

Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines. 2016;15(8):967–76.

Zuber PLF, Autran B, Asturias EJ, Evans S, Hartigan-Go K, Hussey G, et al. Global safety of vaccines: Strengthening systems for monitoring, management and the role of GACVS. Expert Rev Vaccines. 2009;8(6):705–16.

WHO. Adverse events following immunization and causality assessment of an adverse event following immunization. Vol. 16, Chinese Journal of Contemporary Pediatrics. 2014. 1–4 p.

Dieudonné Y, Uring-Lambert B, Jeljeli MM, Gies V, Alembik Y, Korganow AS, et al. Immune Defect in Adults With Down Syndrome: Insights Into a Complex Issue. Front Immunol. 2020;11(May):1–7.

Amanzio M, Mitsikostas DD, Giovannelli F, Bartoli M, Cipriani GE, Brown WA. Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review. The Lancet Regional Health - Europe. 2022;12:100253.

Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663–79.

Raw RK, Rees J, Kelly C, Wroe C, Chadwick DR. Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine. Vaccine. 2021.

Wi YM, Kim SH, Peck KR. Early adverse events between mrna and adenovirus-vectored COVID-19 vaccines in healthcare workers. Vaccines (Basel). 2021;9(8):1–7.